CY1121868T1 - Πεπτιδια και νανοσωματιδια για ενδοκυτταρικη διανομη μοριων - Google Patents

Πεπτιδια και νανοσωματιδια για ενδοκυτταρικη διανομη μοριων

Info

Publication number
CY1121868T1
CY1121868T1 CY20191100822T CY191100822T CY1121868T1 CY 1121868 T1 CY1121868 T1 CY 1121868T1 CY 20191100822 T CY20191100822 T CY 20191100822T CY 191100822 T CY191100822 T CY 191100822T CY 1121868 T1 CY1121868 T1 CY 1121868T1
Authority
CY
Cyprus
Prior art keywords
peptides
nanoparticles
molecule delivery
intracellular molecule
delivery
Prior art date
Application number
CY20191100822T
Other languages
Greek (el)
English (en)
Inventor
Gilles Divita
Neil Desai
Original Assignee
Aadigen, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aadigen, Llc filed Critical Aadigen, Llc
Publication of CY1121868T1 publication Critical patent/CY1121868T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
CY20191100822T 2014-12-24 2019-08-01 Πεπτιδια και νανοσωματιδια για ενδοκυτταρικη διανομη μοριων CY1121868T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1403004 2014-12-24
PCT/EP2015/081197 WO2016102687A1 (en) 2014-12-24 2015-12-23 Peptides and nanoparticles for intracellular delivery of molecules

Publications (1)

Publication Number Publication Date
CY1121868T1 true CY1121868T1 (el) 2020-10-14

Family

ID=55174604

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100822T CY1121868T1 (el) 2014-12-24 2019-08-01 Πεπτιδια και νανοσωματιδια για ενδοκυτταρικη διανομη μοριων

Country Status (18)

Country Link
US (2) US10745440B2 (enExample)
EP (2) EP3237436B1 (enExample)
JP (1) JP6768664B2 (enExample)
CN (1) CN107548401A (enExample)
AU (1) AU2015370926B2 (enExample)
CA (1) CA2971643C (enExample)
CY (1) CY1121868T1 (enExample)
DK (1) DK3237436T3 (enExample)
ES (1) ES2743188T3 (enExample)
HR (1) HRP20191400T1 (enExample)
HU (1) HUE046054T2 (enExample)
IL (1) IL252810B (enExample)
LT (1) LT3237436T (enExample)
MX (1) MX387665B (enExample)
PL (1) PL3237436T3 (enExample)
PT (1) PT3237436T (enExample)
WO (1) WO2016102687A1 (enExample)
ZA (1) ZA201704364B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP3237436B1 (en) 2014-12-24 2019-05-01 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
CA3025523A1 (en) * 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
CA3039797A1 (en) * 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
EP3581190B1 (en) 2016-12-09 2021-03-10 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
JP2020530463A (ja) * 2017-08-10 2020-10-22 アーディジェン， エルエルシー ウイルスの細胞内送達のためのペプチドおよびナノ粒子
CN109557067B (zh) * 2017-09-26 2021-07-20 中国科学院烟台海岸带研究所 一种核—卫星结构金纳米颗粒及其制备方法
JP7395483B2 (ja) * 2017-10-16 2023-12-11 アーディジェン， エルエルシー ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子
CN108424437B (zh) * 2018-02-08 2021-06-22 青岛农业大学 一种递送分子及纳米颗粒、制备方法、用途
EP3833676B1 (en) * 2018-08-07 2025-05-28 ETH Zürich Polypeptides self-assembling into nanoparticles
WO2020214846A1 (en) * 2019-04-17 2020-10-22 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
US20220389057A1 (en) 2019-06-07 2022-12-08 Szegedi Tudományegyetem Endocytosis routing sequence peptide for cell delivery systems
KR102146392B1 (ko) * 2019-06-11 2020-08-21 한림대학교 산학협력단 포스포글리세레이트 뮤테이즈 1 융합단백질 및 이를 포함하는 약학 조성물
CN110540992B (zh) * 2019-08-21 2021-02-09 武汉泽智生物医药有限公司 增强靶基因沉默效率的siRNA分子及其应用
SMT202600194T1 (it) 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用
EP4185602A1 (en) 2020-07-24 2023-05-31 Aadigen, LLC Compositions and methods for treating viral infections
CN113563429A (zh) * 2021-07-19 2021-10-29 天津大学 一种基于烷基化多肽的核酸递送系统及制备方法与应用
US20250295806A1 (en) * 2022-05-05 2025-09-25 Case Western Reserve University Immunostimulatory nanoparticle
US20240366521A1 (en) * 2023-01-17 2024-11-07 Qana Therapeutics Inc. Nanoparticles and methods of use
WO2024187174A2 (en) 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
EP4777526A1 (en) 2023-09-12 2026-07-22 Aadigen, LLC Methods and compositions for treating or preventing cancer
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2025193917A1 (en) * 2024-03-14 2025-09-18 Day Emily Antibody and sirna nanocarriers and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657039B1 (en) 1992-08-25 1998-12-16 MERCK PATENT GmbH Paper white pdlc system
US7514530B2 (en) 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
GB0513096D0 (en) * 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
ATE490266T1 (de) 2005-12-06 2010-12-15 Centre Nat Rech Scient In zellen eindringende peptide als träger für moleküle
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008036929A2 (en) 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Complex for transferring an anionic substance into a cell
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2012137036A1 (en) 2011-04-04 2012-10-11 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2013098813A1 (en) * 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
WO2013173307A1 (en) * 2012-05-16 2013-11-21 Neil Desai Multi-target modulation for treating fibrosis and inflammatory conditions
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053880A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
EP3237436B1 (en) 2014-12-24 2019-05-01 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules

Also Published As

Publication number Publication date
PT3237436T (pt) 2019-08-05
CA2971643A1 (en) 2016-06-30
IL252810A0 (en) 2017-08-31
MX387665B (es) 2025-03-18
JP2018504896A (ja) 2018-02-22
JP6768664B2 (ja) 2020-10-14
US11713336B2 (en) 2023-08-01
HRP20191400T1 (hr) 2019-11-15
US20190002499A1 (en) 2019-01-03
ES2743188T3 (es) 2020-02-18
IL252810B (en) 2022-01-01
WO2016102687A1 (en) 2016-06-30
CA2971643C (en) 2024-03-12
EP3237436B1 (en) 2019-05-01
ZA201704364B (en) 2019-09-25
HUE046054T2 (hu) 2020-01-28
US10745440B2 (en) 2020-08-18
DK3237436T3 (da) 2019-08-12
AU2015370926B2 (en) 2020-07-02
AU2015370926A1 (en) 2017-07-13
MX2017007919A (es) 2018-04-13
US20210032290A1 (en) 2021-02-04
PL3237436T3 (pl) 2020-03-31
EP3556768A1 (en) 2019-10-23
LT3237436T (lt) 2019-09-25
CN107548401A (zh) 2018-01-05
EP3237436A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
MX387665B (es) Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
AU2022206789B2 (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
CY2024034I1 (el) Χιμαιρικες πρωτεϊνες παραγοντα viii και χρησεις αυτων
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1121571T1 (el) Ανοσορρυθμιστες
CY1118869T1 (el) Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου
IL258501B (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3662913A4 (en) Nucleic-acid-containing lipid nanoparticles
DK3538559T3 (da) Rekombinante pmhc klasse ii-molekyler
EP4218904C0 (en) TEMPERATURE MEASUREMENT IN TUMOR TREATMENT FIELD DISTRIBUTION NETWORKS
EP3825400C0 (en) MULTIMERIC ENCODING NUCLEIC ACID AND ITS USES
EP3368089C0 (en) NANOPARTICLE FORMULATIONS FOR THE ADMINISTRATION OF NUCLEIC ACID COMPLEXES
EP3317420A4 (en) EXACT MOLECULAR DECONVOLUTION OF MIXTURE SAMPLES
EP3919505C0 (en) USES OF CAS9 NUCLEIC ACID COMPLEXES
ITUB20152605A1 (it) Avantreno di motoveicolo tiltante e relativo motoveicolo
ITUB20152613A1 (it) Avantreno di motoveicolo tiltante e relativo motoveicolo
MX381016B (es) Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
CY1120569T1 (el) Πρωτεϊνες ειδικες για baff και b7rp1 και χρησεις αυτων
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
CY1122935T1 (el) Ενισχυτικα της υδατοδιαλυτοτητας που βασιζονται στο γλυκογονο
EP3611178A4 (en) LIPID DERIVATIVE FOR INTRODUCTION OF NUCLEIC ACID